Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with...
-
Feintool Sustainability Report 2021 Feintool has defined specific climate targets for the Group: By 2030, the technology group aims to reduce CO2 emissions from its own business...
-
Feintool Nachhaltigkeitsbericht 2021 Feintool hat für die Gruppe konkrete Klimaziele definiert: Bis 2030 will der Technologiekonzern die CO2-Emissionen aus eigener...
-
Basel, 27. April 2022 Basilea Pharmaceutica AG (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten, und dem Ziel, Patienten zu helfen, die an Infektionen durch...
-
Basel, Switzerland, April 27, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with bacterial and fungal...
-
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Restatement of 2020 financial statements required, implying a continuing operations EBITDA margin of 15.5 % (preliminary, unaudited) vs. 15.0 %...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
-
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
-
26 April 2022, 17:00 CET ArcelorMittal (the ‘Company’) today announces that it has completed its US$1 billion share buyback program announced on 11 February 2022 under the authorization given by the...
-
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte den Umsatz...